Distillery: Techniques

October 29 2009, Volume 2 / Number 42

Top

Assays and screens

Prostate-specific antigen (PSA) assay for early detection of prostate cancer recurrence

doi:10.1038/scibx.2009.1580

An assay for the immunological detection of PSA could help predict the recurrence of prostate cancer earlier than existing methods.

Top

Computational models

Marker interaction–based algorithms to improve genotype-based disease risk assessment

doi:10.1038/scibx.2009.1581

Including interactions between large groups of markers could be useful for improving disease risk assessment.

Top

Disease models

Mouse model of sudden unexplained death in epilepsy (SUDEP)

doi:10.1038/scibx.2009.1582

Mice expressing a mutant potassium channel Kv7. (Kcnq1) could help identify therapies to prevent SUDEP.

Top

Drug delivery

Extending the half-life of mAb therapeutics by blocking proteolytic cleavage

doi:10.1038/scibx.2009.1583

A study in cell culture, human tissue and mice suggests that blocking proteases could extend the half-life of mAb therapeutics.

Top

Drug platforms

Chemical platform for generation of human induced pluripotent stem (iPS) cells

doi:10.1038/scibx.2009.1584

A cocktail of three small molecules may provide a chemical platform for optimizing the production of human iPS cells for cell-replacement therapies.

Infectious agent–neutralizing, bifunctional small molecules that recruit naturally occurring dinitrophenol (DNP) antibodies

doi:10.1038/scibx.2009.1585

Bifunctional small molecules containing an infectious agent–targeting moiety linked to DNP could help treat infectious diseases.

Top

Markers

Molecular markers of truly pluripotent human induced pluripotent stem (iPS) cells

doi:10.1038/scibx.2009.1586

A set of three molecular markers for identifying human iPS cells could help optimize iPS cell applications for research and cell therapies.

Myeloid leukemia cell differentiation protein (Mcl-1) dependency as a marker for chemotherapy sensitivity

doi:10.1038/scibx.2009.1587

Studies in cell culture suggest that leukemia cells that depend on Mcl-1 for survival could be more sensitive to chemotherapy than BCL2-dependent cells.